Breaking News Instant updates and real-time market news.

CCE

Symbol CCEP

$37.22

-0.18 (-0.48%)

07:40
02/15/18
02/15
07:40
02/15/18
07:40

Coca-Cola European Partners reports Q4 EPS comparable basis EUR0.49

Fourth-quarter 2017 diluted earnings per share were EUR0.49 on a comparable basis. Currency translation had a negligible impact on fourth-quarter comparable diluted earnings per share. Fourth-quarter reported operating profit totalled EUR$198M, up 50% versus prior year. Comparable operating profit was EURO$341M, up 9.5%, or up 10% on a comparable and fx-neutral basis. Fourth-quarter 2017 reported revenue totalled EUR$2.7B up 3.5%, or up 4% on a comparable and fx-neutral basis. Revenue per unit case was up 3% on a comparable and fx-neutral basis driven by favourable price, promotion and channel mix. Fourth-quarter volume increased 0.5% on a comparable basis, reflecting solid field sales execution and the benefits of marketing and brand initiatives.

  • 19

    Feb

CCE Symbol CCEP
$37.22

-0.18 (-0.48%)

11/13/17
SUSQ
11/13/17
DOWNGRADE
SUSQ
Negative
Coca-Cola European Partners downgraded to Negative from Neutral at Susquehanna
11/13/17
SUSQ
11/13/17
DOWNGRADE
Target $33
SUSQ
Negative
Coca-Cola European Partners downgraded to Negative at Susquehanna
As previously reported, Susquehanna analyst Pablo Zuanic downgraded Coca-Cola European Partners to Negative from Neutral. The analyst believes current consensus estimates do not properly reflect the challenges ahead, including the U.K. sugar tax, foreign exchange inflation, higher input costs, slower tourism, and further regulatory risk. Zuanic lowered his price target to $33 from $38 on Coca-Cola European Partners shares.
12/13/17
DBAB
12/13/17
INITIATION
Target $43
DBAB
Buy
Coca-Cola European Partners initiated with a Buy at Deutsche Bank
Deutsche Bank analyst Steve Powers started Coca-Cola European Partners with a Buy rating and $43 price target. The analyst believes concerns over carbonated soft drinks are pricing into the shares, leaving "optionality skewed to the upside."
01/05/18
MACQ
01/05/18
DOWNGRADE
Target $40
MACQ
Neutral
Coca-Cola European Partners downgraded to Neutral from Outperform at Macquarie
Macquirie analyst Caroline Levy downgraded Coca-Cola European Partners to Neutral from Outperform and lowered is price target to $40 from $45. Levy cites volume pressures, especially in France, input cost pressures, margin pressures, and lack of M&A for the downgrade and expects growth to slow to 4% in FY18 from 11% in FY17.

TODAY'S FREE FLY STORIES

DRI

Darden

$116.11

7.485 (6.89%)

05:53
03/22/19
03/22
05:53
03/22/19
05:53
Recommendations
Darden analyst commentary  »

Darden price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMC

Commercial Metals

$17.35

1.29 (8.03%)

05:43
03/22/19
03/22
05:43
03/22/19
05:43
Upgrade
Commercial Metals rating change  »

Commercial Metals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SWK

Stanley Black & Decker

$134.59

2.69 (2.04%)

05:42
03/22/19
03/22
05:42
03/22/19
05:42
Upgrade
Stanley Black & Decker rating change  »

Stanley Black &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Apr

  • 24

    Apr

BIIB

Biogen

$226.71

-93.76 (-29.26%)

05:42
03/22/19
03/22
05:42
03/22/19
05:42
Downgrade
Biogen rating change  »

Biogen downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 24

    Apr

  • 30

    Apr

  • 01

    May

  • 28

    May

BBY

Best Buy

$70.56

1.44 (2.08%)

05:41
03/22/19
03/22
05:41
03/22/19
05:41
Upgrade
Best Buy rating change  »

Best Buy upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VAR

Varian Medical

$137.77

1.97 (1.45%)

05:41
03/22/19
03/22
05:41
03/22/19
05:41
Upgrade
Varian Medical rating change  »

Varian Medical upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

BIIB

Biogen

$226.71

-93.76 (-29.26%)

05:41
03/22/19
03/22
05:41
03/22/19
05:41
Downgrade
Biogen rating change  »

Citi downgrades Biogen to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 24

    Apr

  • 30

    Apr

  • 01

    May

  • 28

    May

FTI

TechnipFMC

$23.83

0.09 (0.38%)

05:40
03/22/19
03/22
05:40
03/22/19
05:40
Upgrade
TechnipFMC rating change  »

TechnipFMC upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

RYB

RYB Education

$8.01

0.09 (1.14%)

05:40
03/22/19
03/22
05:40
03/22/19
05:40
Downgrade
RYB Education rating change  »

RYB Education downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOV

Spark Networks

$11.29

(0.00%)

05:26
03/22/19
03/22
05:26
03/22/19
05:26
Conference/Events
Spark Networks to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Mar

ESALY

Eisai

$0.00

(0.00%)

05:25
03/22/19
03/22
05:25
03/22/19
05:25
Downgrade
Eisai rating change  »

Eisai downgraded to Sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESALY

Eisai

$0.00

(0.00%)

, BIIB

Biogen

$226.71

-93.76 (-29.26%)

05:24
03/22/19
03/22
05:24
03/22/19
05:24
Hot Stocks
Eisai announces initiation of Phase III BAN2401 study in Alzheimer's disease »

Eisai (ESALY) announced…

ESALY

Eisai

$0.00

(0.00%)

BIIB

Biogen

$226.71

-93.76 (-29.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 24

    Apr

  • 30

    Apr

  • 01

    May

  • 28

    May

ZUO

Zuora

$24.34

0.62 (2.61%)

05:18
03/22/19
03/22
05:18
03/22/19
05:18
Recommendations
Zuora analyst commentary at Jefferies »

Zuora business metrics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

OPHRY

Ophir Energy

$0.00

(0.00%)

05:15
03/22/19
03/22
05:15
03/22/19
05:15
Downgrade
Ophir Energy rating change  »

Ophir Energy downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TELNY

Telenor

$0.00

(0.00%)

05:13
03/22/19
03/22
05:13
03/22/19
05:13
Downgrade
Telenor rating change  »

Telenor downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KGFHY

Kingfisher

$0.00

(0.00%)

05:13
03/22/19
03/22
05:13
03/22/19
05:13
Downgrade
Kingfisher rating change  »

Kingfisher downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HIIQ

Health Insurance Innovations

$31.29

0.78 (2.56%)

05:11
03/22/19
03/22
05:11
03/22/19
05:11
Earnings
Health Insurance confirms 2019 outlook, calls shares 'compelling value' »

Health Insurance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

HIIQ

Health Insurance Innovations

$31.29

0.78 (2.56%)

05:07
03/22/19
03/22
05:07
03/22/19
05:07
Hot Stocks
Health Insurance CEO says multi-state regulatory review found no issues »

Health Insurance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

PSO

Pearson

$10.96

0.07 (0.64%)

05:02
03/22/19
03/22
05:02
03/22/19
05:02
Upgrade
Pearson rating change  »

Pearson upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LITE

Lumentum

$52.05

2.395 (4.82%)

04:59
03/22/19
03/22
04:59
03/22/19
04:59
Upgrade
Lumentum rating change at JPMorgan »

Lumentum upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

PPG

PPG

$112.60

1.73 (1.56%)

04:58
03/22/19
03/22
04:58
03/22/19
04:58
Downgrade
PPG rating change at JPMorgan »

PPG downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Apr

SHW

Sherwin-Williams

$433.70

4.385 (1.02%)

04:57
03/22/19
03/22
04:57
03/22/19
04:57
Downgrade
Sherwin-Williams rating change at JPMorgan »

Sherwin-Williams…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Apr

MDB

MongoDB

$154.52

10.73 (7.46%)

04:55
03/22/19
03/22
04:55
03/22/19
04:55
Initiation
MongoDB initiated at William Blair »

MongoDB initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

04:55
03/22/19
03/22
04:55
03/22/19
04:55
General news
Breaking General news story  »

Week of 3/22 Baker-Hughes…

04:55
03/22/19
03/22
04:55
03/22/19
04:55
General news
Wholesale Trade Inventories to be reported at 10:00 »

January Wholesale Trade…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.